Cochrane Database of Systematic Reviews (Reviews) || Vasopressin and its analogues for the treatment...
Transcript of Cochrane Database of Systematic Reviews (Reviews) || Vasopressin and its analogues for the treatment...
Vasopressin and its analogues for the treatment of refractory
hypotension in neonates (Review)
Shivanna B, Rios D, Rossano J, Fernandes CJ, Pammi M
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library2013, Issue 3
http://www.thecochranelibrary.com
Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iVasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Vasopressin and its analogues for the treatment of refractoryhypotension in neonates
Binoy Shivanna1, Danielle Rios1 , Joseph Rossano2 , Caraciolo J Fernandes1, Mohan Pammi1
1Section of Neonatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA. 2The Children’s Hospital of
Philadelphia, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Contact address: Mohan Pammi, Section of Neonatology, Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza,
Houston, Texas, 77030, USA. [email protected]. [email protected].
Editorial group: Cochrane Neonatal Group.
Publication status and date: New, published in Issue 3, 2013.
Review content assessed as up-to-date: 15 July 2012.
Citation: Shivanna B, Rios D, Rossano J, Fernandes CJ, Pammi M. Vasopressin and its analogues for the treatment
of refractory hypotension in neonates. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD009171. DOI:
10.1002/14651858.CD009171.pub2.
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Neonatal hypotension that is refractory to volume expansion, catecholamines, or corticosteroids has a mortality of about 50%. Opti-
mization of blood pressure and tissue perfusion in refractory hypotension may be crucial to improve clinical outcomes. Vasopressin, a
neuropeptide hormone, or its analogue terlipressin has been used to treat refractory hypotension in neonates and may be effective.
Objectives
Our primary objective was to evaluate the efficacy and safety of vasopressin and its synthetic analogues (e.g. terlipressin) in decreasing
mortality and adverse neurodevelopmental outcomes, and improving survival in neonates with refractory hypotension. Our secondary
objectives were to determine the effects of vasopressin and its analogues (terlipressin) on improvement in blood pressure, increase in
urine output, decrease in inotrope score, necrotizing enterocolitis (NEC), periventricular leukomalacia, intraventricular hemorrhage,
chronic lung disease, and retinopathy of prematurity (ROP) in neonates with refractory hypotension.
Search methods
We searched the literature in January 2012, using the search strategy recommended by the Cochrane Neonatal Group. We searched
electronic databases (CENTRAL (The Cochrane Library), MEDLINE, CINAHL, EMBASE), abstracts of the Pediatric Academic
Societies, web sites for registered trials at www.clinicaltrials.gov and www.controlled-trials.com and in the reference list of identified
articles.
Selection criteria
Randomized or quasi-randomized trials evaluating vasopressin or its analogues, at any dosage or duration used as an adjunct to standard
therapy (any combination of volume expansion, inotropic agents and corticosteroids) to treat refractory hypotension in neonates.
Data collection and analysis
We followed the standard methods of The Cochrane Collaboration for conducting a systematic review. Two review authors (BS and
MP) independently assessed the titles and abstracts of studies identified by the search strategy for eligibility for inclusion. We obtained
the full text version if eligibility could not be done reliably by title and abstract. We resolved any differences by mutual discussion.
We designed electronic forms for trial inclusion/exclusion, data extraction, and for requesting additional published information from
authors of the original reports.
1Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
Our search did not identify any completed or ongoing trials that met our inclusion criteria. Three studies that did not include neonates
and one study where the objective was not to treat neonates with refractory hypotension were excluded.
Authors’ conclusions
There is insufficient evidence to recommend or refute the use of vasopressin or its analogues in the treatment of refractory hypotension
in neonates. Well-designed, adequately powered, randomized controlled studies are necessary to address efficacy, optimal dosing, safety
and long-term neurodevelopmental and pulmonary outcomes.
P L A I N L A N G U A G E S U M M A R Y
Vasopressin and its analogues for the treatment of refractory hypotension in neonates
Hypotension or low blood pressure occurs frequently in newborn infants after infection or surgery or in very preterm infants. Sometimes,
the hypotension does not respond to fluids or other drug such as catecholamines or steroids. In those unresponsive infants, vasopressin
may be useful in improving blood pressure and overall survival. We searched the literature for studies that used vasopressin or its
analogue terlipressin in the newborn in the first 28 days of life for unresponsive hypotension. We found no ongoing or completed
studies. Currently there is no evidence to recommend the use of vasopressin or terlipressin, but we recommend that studies be carried
out in the future to study the effectiveness and safety in unresponsive hypotension in newborn infants.
B A C K G R O U N D
Description of the condition
Hypotension is a significant problem in preterm, septic, and post-
surgical neonates. Symptomatic hypotension (hypotension requir-
ing treatment) is associated with significant morbidity. In a case-
control study of 156 extremely low birth weight infants (ELBW,
birth weight less than 1000 g), symptomatic hypotension in the
first 72 hours of life was associated with a severe grade of intraven-
tricular hemorrhage (IVH), higher mortality, increased hearing
loss, and adverse neurodevelopmental outcomes (Fanaroff 2006).
In preterm infants, hypotension may be associated with neonatal
cerebral injury resulting in adverse long-term neurodevelopmental
outcomes (Low 1993; Goldstein 1995).
Normal blood pressure is defined by blood pressure between the 10th and 90th percentiles that are appropriate for postmenstrual age
(Nuntnarumit 1999). The 10th percentile for the mean blood pres-
sure approximately equals the gestational age in the first 48 hours
of life (Hegyi 1994). Impairment of cerebral blood flow and associ-
ated cerebral injury at mean blood pressures of less than 30 mmHg
has been reported, which has prompted some neonatologists to
treat neonates with a mean BP below this threshold (Miall-Allen
1987; Tsuji 2000; Munro 2004). Therapeutic measures for neona-
tal hypotension include volume expansion (bolus of crystalloids
or colloids), inotropic agents (catecholamines: dopamine, dobu-
tamine, epinephrine or rarely norepinephrine) and corticosteroids
(hydrocortisone or dexamethasone) (Pladys 1999; Al-Aweel 2001;
Seri 2001; Dempsey 2006). Strong evidence to support one ther-
apy over the other for the treatment of neonatal hypotension is
lacking. Evidence is insufficient not only regarding the use of
fluid boluses in the treatment of neonatal hypotension, but also
with the type of fluid used (colloid or crystalloid) (Osborn 2004).
Dopamine increases mean blood pressure better than fluid bo-
luses (Osborn 2001) or dobutamine (Subhedar 2003), but it does
not decrease mortality or adverse neurodevelopmental outcomes.
The efficacy of epinephrine (Paradisis 2004) and corticosteroids
(Subhedar 2007) in the treatment of neonatal hypotension in im-
proving the outcomes of mortality or adverse neurodevelopmental
outcomes is yet to be proven.
Refractory hypotension in the newborn is defined as a hypotension
with signs of inadequate perfusion despite volume expansion and
administration of inotropic agents and/or corticosteroids (Sarkar
2007; Baker 2008; Bidegain 2010). Refractory hypotension has an
estimated mortality of about 50% (Bidegain 2010; Meyer 2006a;
Meyer 2006b) and can result in significant morbidity in critically
ill neonates (Meyer 2006b; Rodriguez-Nunez 2006; Leone 2008).
Therefore, optimization of blood pressure and tissue perfusion in
refractory hypotension may be crucial to improve clinical out-
comes.
2Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Description of the intervention
Arginine vasopressin (AVP) is a neuropeptide hormone secreted
by the posterior pituitary that regulates sodium homeostasis and
serum osmolality. AVP is released into the circulation in response
to high plasma osmolality or as a baroreceptor response to hypo-
volemia. In health, AVP secretion is tightly regulated by changes
in serum osmolality. In contrast, the baroreceptor-mediated regu-
lation of AVP secretion is regulated by a fall in blood pressure (>
10%) (Mutlu 2004).
Terlipressin, tri-cycl-lysine-vasopressin, is a synthetic long-acting
analogue of AVP. Terlipressin has a higher affinity for vascular
receptors and similar pharmacodynamic properties compared to
AVP. Terlipressin is a prodrug that is rapidly metabolized by en-
dothelial peptidases to the vasoactive lysine-vasopressin. The half-
life of terlipressin is six hours compared to the short half-life of
AVP (six minutes). The pharmacokinetics of terlipressin suggests
that an intermittent intravenous dosing schedule of every four to
12 hours would be appropriate, as opposed to continuous infusion
of AVP (Pesaturo 2006).
The adverse effects of AVP and terlipressin therapy in human
neonates and infants have not been investigated thoroughly. Liver
necrosis after AVP (Meyer 2006a), and splanchnic, digital and skin
ischemia with terlipressin have been reported (Rodriguez-Nunez
2006; Zeballos 2006).
How the intervention might work
AVP mediates the cardiovascular and renal effects via at least three
known receptor subtypes (V1, V2 and V3). AVP exerts a di-
rect vasoconstrictive effect by acting on the V1 receptors that are
predominantly found on vascular smooth muscle cells and my-
ocardium. V1 receptors are also found on the hepatocytes and
platelets, which may result in platelet aggregation and glycogenol-
ysis during AVP therapy. The receptors are linked to a phospho-
inositol signaling pathway with intracellular calcium acting as a
second messenger (Holmes 2001). Other probable indirect effects
of AVP on vascular smooth muscle cells leading to vasoconstric-
tion include local inhibition of nitric oxide production (Kusano
1997) and inhibition of smooth muscle cell K+-ATP channels
(Wakatsuki 1992). When compared with AVP, terlipressin has a
greater selectivity for the V1 receptor over the V2 receptor (Nilsson
1990). The rationale for using AVP or terlipressin in refractory
hypotension is based on a biphasic response of endogenous AVP in
adults with septic shock, with initial high levels followed by inap-
propriately low levels (Argenziano 1998; Patel 2002). Therefore,
in vasodilatory shock, a relative AVP deficiency exists that may be
corrected by administration of AVP. Currently, AVP and its ana-
logue, terlipressin, are being increasingly used as a rescue therapy
for hypotension refractory to high-dose catecholamine and cor-
ticosteroids in neonates with sepsis (Matok 2004; Matok 2005;
Leone 2008; Bidegain 2010), cardiogenic shock (Meyer 2006b;
Lechner 2007), necrotizing enterocolitis (NEC) (Bidegain 2010),
non-septic shock with acute renal injury (Meyer 2006a), and sys-
temic inflammatory response syndrome following surgery (Filippi
2008). In neonatal studies, dosages of AVP ranged between 0.01
to 0.36 units/kg/hour, and terlipressin from 7 µg/kg twice a day
to 2 µg/kg every four hours. Terlipressin increases the mean blood
pressure by approximately 30% in neonates and infants. The ef-
fect was more pronounced in patients who survived than in those
who died (Matok 2005; Leone 2008).
Why it is important to do this review
Optimal management of refractory hypotension in high-risk
neonates has the potential to improve neonatal outcomes. This re-
view aims to systematically review the literature to investigate the
roles of vasopressin and terlipressin in the treatment of refractory
hypotension in neonates and to identify gaps in knowledge that
will inform future clinical trials.
O B J E C T I V E S
Primary objective
To evaluate the efficacy and safety of vasopressin and its syn-
thetic analogues (e.g. terlipressin) in decreasing mortality and ad-
verse neurodevelopmental outcomes, and improving survival in
neonates with refractory hypotension.
Secondary objectives
To determine the effects of vasopressin and its analogues (terli-
pressin) on improvement in blood pressure, increase in urine out-
put, decrease in inotrope score (Wernovsky 1995; Lechner 2007),
NEC, periventricular leukomalacia (PVL), IVH, chronic lung dis-
ease (CLD), and retinopathy of prematurity (ROP) in neonates
with refractory hypotension.
We planned to analyze the following subgroups if data had been
available.
1. Gestational age:
• term;
• preterm (28 to 37 weeks);
• extremely preterm (less than 28 weeks).
2. Birth weight:
• birth weight more than 2500 g;
• birth weight from 1000 to 2500 g;
• ELBW less than 1000 g.
3. Patient subgroups:
3Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• sepsis;
• post-cardiac surgery;
• NEC.
4. Subgroups of intervention:
• vasopressin;
• terlipressin.
5. Severity of hypotension:
• catecholamine-resistant hypotension;
• catecholamine and steroid-resistant hypotension.
Comparisons
1. Vasopressin and its analogues in the treatment of refractory
hypotension in neonates as an adjunct to standard therapy versus
standard therapy alone (combination of volume expansion,
catecholamines and corticosteroids).
2. Vasopressin and its analogues in the treatment of refractory
hypotension in neonates as an adjunct to therapy with
catecholamines and corticosteroids versus catecholamine and
corticosteroids.
3. Vasopressin and its analogues in the treatment of refractory
hypotension in neonates as an adjunct to catecholamines versus
catecholamines alone.
4. Vasopressin and its analogues in the treatment of refractory
hypotension in neonates as an adjunct to corticosteroids versus
corticosteroids alone.
5. Vasopressin and its analogues in the treatment of refractory
hypotension in neonates as an adjunct to volume expansion
versus volume expansion alone.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized or quasi-randomized controlled trials, cluster-ran-
domized trials or randomized cross-over trials.
Types of participants
Any neonate (less than 28 days of age), term or preterm, with
refractory hypotension. Refractory hypotension in the newborn
is defined as a hypotension with signs of metabolic and lactic
acidemia despite volume expansion and administration of in-
otropic agents and corticosteroids (Sarkar 2007; Baker 2008;
Bidegain 2010).
Types of interventions
Vasopressin and its analogue terlipressin at any dosage or duration
used as an adjunct to standard therapy to treat refractory hypoten-
sion in neonates.
Standard therapy of neonatal hypotension is any combination of
volume expansion, inotropic agents and corticosteroids.
Types of outcome measures
Primary outcomes
1. Efficacy as measured by any of the following:
i) mortality: ’all-cause mortality’ during hospital stay.
ii) survival at 18 or more months of age.
iii) neurodevelopmental outcome assessed by a validated
test at 18 or more months of age.
Secondary outcomes
i) Increase in mean blood pressure greater than the 10th
percentile for the postmenstrual age (Nuntnarumit 1999) OR
increase in mean blood pressure greater than 30 mm Hg in
preterm infants, irrespective of their postmenstrual age
(Miall-Allen 1987).
ii) Increase in urine output greater than 1 ml/kg/hour
over eight hours.
iii) Decrease in inotrope requirements as determined by
inotrope score. Scores calculated before and after vasopressin
therapy of at least 30 minutes. Inotrope score = dopamine +
dobutamine + epinephrine x 100 + norepinephrine x 100, all
dosages in micrograms per kilogram per minute (Wernovsky
1995; Lechner 2007).
iv) NEC (definite NEC and perforated NEC, Bell’s stage
II or III) (Bell 1978).
v) CLD defined as oxygen requirement at 36 weeks
postmenstrual age (Jobe 2001).
vi) PVL (defined as necrosis of white matter in a
characteristic distribution, i.e., in the white matter dorsal and
lateral to the external angles of lateral ventricles involving
particularly the centrum semi ovale, optic and acoustic radiations
and diagnosed by magnetic resonance imaging (MRI) (Volpe
2008).
vii) IVH- severe grade III or IV (Papile 1978).
viii) ROP stages III and IV (ICROP 1984).
ix) Safety: Monitored for adverse effects of hyponatremia
(serum sodium (Na) less than 130 mEq/L), limb and skin
ischemia (evaluated clinically by mottling or discoloration),
myocardial ischemia (EKG changes or elevation of cardiac
enzymes CPK-MB or troponins).
4Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Search methods for identification of studies
We searched the literature using the search strategy recommended
by the Cochrane Neonatal Group (CNRG), in January 2012 from
the following sources.
1. The Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library).2. Electronic journal reference databases: MEDLINE (1966 to
present) and PREMEDLINE, EMBASE (1980 to January
2012), CINAHL (1982 to January 2012).
3. We searched for ongoing trials in the following databases at
the following web sites: www.clinicaltrials.gov and
www.controlled-trials.com.
4. We searched abstracts of conferences - proceedings of
Pediatric Academic Societies (American Pediatric Society, Society
for Pediatric Research and European Society for Pediatric
Research) from 1990 from the journal ’Pediatric Research’ and
Abstracts online.
5. We contacted authors who published in this field for
possible unpublished articles.
6. We also searched from the reference list of identified clinical
trials and in the review authors’ personal files.
Search strategy for MEDLINE and PREMEDLINE. We adapted
this strategy to suit EMBASE, CINAHL and the Cochrane Con-
trolled Trials Register.
# 1 explode ’hypotension’ [all subheadings in MIME, MJME]
# 2 explode “shock’
# 3 ‘refractory hypotension”
# 4 “catecholamine refractory hypotension”
# 5 ’hypoperfusion’
# 6 # 1 or # 2 or # 3 or # 4 or # 5
# 7 explode ’infant - newborn’ [all subheadings in MIME, MJME]
# 8 Neonat*
# 9 Newborn*
# 10 # 7 or # 8 or # 9
# 11 # 6 and # 10
# 12 “vasopressin’ or pitressin [all subheadings on MIME, MJME]
# 13 terlipressin or glypressin or glycylpressin or remestyp
# 14 # 12 or # 13
# 15 # 11 and # 14
We did not apply language restriction. We sought randomized,
quasi-randomized trials, cluster-randomized and cross-over trials
from the search results.
Data collection and analysis
We followed the standard methods of The Cochrane Collabora-
tion for conducting a systematic review.
Selection of studies
Two review authors (BS and MP) independently assessed the titles
and abstracts of studies identified by the search strategy for eligi-
bility for inclusion in this review. We obtained the full text version
for assessment, if eligibility could not be assessed reliably by title
and abstract. We resolved any differences by mutual discussion.
We obtained a full text version of all eligible studies for quality
assessment.
Data extraction and management
We designed electronic forms for trial inclusion/exclusion, data
extraction and for requesting additional published information
from authors of the original reports. Two review authors (MP and
BS) performed data extraction independently using specifically
designed electronic spreadsheets. We resolved any differences by
mutual discussion.
Assessment of risk of bias in included studies
There are no included studies in this version of the review. For fu-
ture updates of this review, two review authors will independently
assess the risk of bias for each study when studies for inclusion
are identified, using the criteria outlined in the Cochrane Hand-book for Systematic Reviews of Interventions (Higgins 2011). Any
disagreement will be resolved by discussion with the third review
author (CF).
(1) Sequence generation (checking for possible selection
bias)
If we identify studies that can be included, we will evaluate whether
the method used to generate the allocation sequence was described
in sufficient detail to allow an assessment of whether it should
produce comparable groups. We will assess the methods as:
• low risk (any truly random process, for example, random
number table; computer random number generator);
• high risk (any non-random process, for example, odd or
even date of birth; hospital or clinic record number);
• unclear risk.
(2) Allocation concealment (checking for possible selection
bias)
If we identify studies that can be included, we will evaluate whether
the method used to conceal the allocation sequence was described
in sufficient detail and determine whether intervention allocation
could have been foreseen in advance of, or during recruitment, or
changed after assignment. We will assess the methods as:
• low risk (for example, telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• high risk (open random allocation; unsealed or non-opaque
envelopes, alternation; date of birth);
• unclear risk.
5Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(3) Blinding (checking for possible performance bias)
If we identify studies that can be included, we will describe the
methods used, if any, to blind study participants and personnel
from knowledge of which intervention a participant received. We
will judge studies to be at low risk of bias if they were blinded, or
if we judge that the lack of blinding could not have affected the
results. We will assess blinding separately for different outcomes
or classes of outcomes. We will assess the methods as:
• low risk, high risk or unclear risk for participants;
• low risk, high risk or unclear risk for personnel;
• low risk, high risk or unclear risk for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
If we identify studies that can be included, we will evaluate the
completeness of data including attrition and exclusions from the
analysis. We will state whether attrition and exclusions are re-
ported, the numbers included in the analysis at each stage (com-
pared with the total randomized participants), reasons for attrition
or exclusion where reported, and whether missing data are bal-
anced across groups or are related to outcomes. Where sufficient
information is reported, or can be supplied by the trial authors, we
will re-include missing data in the analyses. We will assess methods
as:
• low risk;
• high risk:
• unclear risk.
(5) Selective reporting bias
If we identify studies that can be included, we will investigate the
possibility of selective outcome reporting bias. We will assess the
methods as:
• low risk (where it is clear that all of the study’s pre-specified
outcomes and all expected outcomes of interest to the review
have been reported);
• high risk (where not all the study’s pre-specified outcomes
have been reported; one or more reported primary outcomes were
not pre-specified; outcomes of interest are reported incompletely
and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear risk.
(6) Other sources of bias
If we identify studies that can be included, we will describe any
important concerns we had about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• yes;
• no;
• unclear risk.
(7) Overall risk of bias
We will evaluate the studies using all of the above criteria and
make explicit judgements about whether studies are at high risk
of bias. With reference to (1) to (6) above, we will assess the likely
magnitude and direction of the bias and whether we consider it
likely to impact on the findings.
If cross-over or cluster-randomized trials are included in future
updates of the review, then risk of bias will be assessed as outlined
in the Cochrane Handbook for Systematic Reviews of Interventions(Higgins 2011).
Measures of treatment effect
We will perform statistical analyses according to the recommen-
dations of the CNRG when data are available. We will analyze all
infants randomized on ’an intention-to-treat basis’ irrespective of
whether they survived or not, to receive their allocated treatment
completely. We will analyze treatment effects in the individual tri-
als, using The Cochrane Collaboration’s statistical analysis pack-
age, Review Manager 5.1 (RevMan 2011).
We will report risk ratio (RR) and risk difference (RD) with 95%
confidence intervals (CIs) for dichotomous outcomes and mean
differences (MD) for continuous outcomes. With outcomes such
as neurodevelopmental outcomes where different scales may be
used to measure outcomes, we will report standard MD. If there
was a statistically significant reduction in RD then we will calculate
the number needed to treat to benefit (NNTB) or number needed
to harm (NNTH). We will use a fixed-effect model for meta-
analysis.
If cross-over or cluster-randomized trials are included in future
updates of the review, then measures of treatment effect will be
assessed as outlined in the Cochrane Handbook for Systematic Re-views of Interventions (Higgins 2011).
Assessment of heterogeneity
We will assess statistical heterogeneity of treatment effects between
trials using the I 2 statistic (RevMan 2011). We will grade degrees
of heterogeneity as low (greater than 25%), moderate (greater than
50%) or high (greater than 75%). If significant heterogeneity is
noted then we will explore sources of heterogeneity by subgroup
or sensitivity analyses.
Data synthesis
We will use RevMan 5.1 software (RevMan 2011) for statistical
analysis and intend to use a fixed-effect model for meta-analysis
when eligible trials are identified.
6Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Subgroup analysis and investigation of heterogeneity
i) Gestational age: term, preterm (28 to 37 weeks),
extremely preterm (less than 28 weeks).
ii) Birth weight: birth weight greater 2500 g, BW 1000
to 2500 g, ELBW less than 1000 g.
iii) Patient subgroups: sepsis, post-cardiac surgery, NEC.
iv) Subgroups of intervention: vasopressin, terlipressin.
v) Severity of hypotension: catecholamine-resistant
hypotension, catecholamine- and steroid-resistant hypotension.
Comparisons
i) Vasopressin and its analogues in the treatment of
refractory hypotension in neonates as an adjunct to standard
therapy versus standard therapy alone (combination of volume
expansion, catecholamines and corticosteroids).
ii) Vasopressin and its analogues in the treatment of
refractory hypotension in neonates as an adjunct to therapy with
catecholamines and corticosteroids versus catecholamine and
corticosteroids.
iii) Vasopressin and its analogues in the treatment of
refractory hypotension in neonates as an adjunct to
catecholamines versus catecholamines alone.
iv) Vasopressin and its analogues in the treatment of
refractory hypotension in neonates as an adjunct to
corticosteroids versus corticosteroids alone.
v) Vasopressin and its analogues in the treatment of
refractory hypotension in neonates as an adjunct to volume
expansion versus volume expansion alone.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
Results of the search
We identified three randomized controlled trials of vasopressin
(Baldasso 2009; Choong 2009; Rios 2011) and one on terlipressin
(Yildizdas 2008) in children. None of the studies met our inclusion
criteria. We excluded the studies because there were no neonates
in the study population in three studies (Yildizdas 2008; Baldasso
2009; Choong 2009) and treatment of refractory hypotension was
not the objective of one study (Rios 2011).
Included studies
There are no included studies.
Excluded studies
Baldasso 2009
Baldasso and co-investigators evaluated the effects of prophylactic
low-dose vasopressin to offset the hypotensive effects of sedation
and analgesia in children expected to require mechanical venti-
lation for more than three days. Twenty-four children were ran-
domized to low-dose vasopressin (0.0005 units/kg/min) or nor-
mal saline for a period of 48 hours (12 in each group). Vasopressin
infusion was associated with a higher incidence of hyponatremia,
decrease in urine output and acute increase in blood pressure. Re-
bound hypotension was also noticed after stopping vasopressin.
This study was excluded as neonates were not included.
Choong 2009
Choong and co-investigators randomized 69 children in vasodila-
tory shock in a multicenter, double-blind trial to low-dose vaso-
pressin (0.0005 to 0.002 units/kg/min) or placebo. Data from 65
children (33 received vasopressin and 32 placebo) were analyzed.
There was no significant difference in the primary outcome of
time to vasoactive-free hemodynamic stability or the secondary
outcomes of mortality (a trend towards increased mortality in the
vasopressin group), organ failure-free days, length of critical care
unit stay or adverse events. This study was excluded as neonates
were not included.
Yildizdas 2008
Yildizdas and co investigators randomized 58 children (age range
one to 156 months) with catecholamine-resistant septic shock to
receive either terlipressin (n = 30) or additional catecholamines (n
= 28). Terlipressin was administered as intravenous bolus doses of
20 micrograms/kg every six hours if necessary (mean arterial blood
pressure was lower than 2 SD (standard deviation)) for a maximum
of 96 hours. A combination of at least two catecholamines were
administered to all patients in both groups. The outcomes assessed
were mean arterial pressure, heart rate, PaO2/FiO2 ratio, duration
of mechanical ventilation, blood urea nitrogen, creatinine, alanine
aminotransferase, aspartate aminotransferase, urine output, cuta-
neous and extremity ischemia findings, length of stay, and mor-
tality. Terlipressin improved mean blood pressure and oxygena-
tion 30 minutes after each terlipressin treatment but not mortal-
ity rate, urine output, or the duration of mechanical ventilation.
Terlipressin use was not associated with any adverse events in this
study. This study was excluded as neonates were not included.
Rios 2011
Rios and co-investigators, in a double-blind randomized con-
trolled trial at a single center (Texas Children’s Hospital) are inves-
tigating the role of vasopressin compared with dopamine for the
treatment of low blood pressure in ELBW infants. ELBW infants
with a birth weight of < 1001 g and/or gestational age of < 29
weeks, who have hypotension in the first 24 hours of life will be
randomized to either a continuous infusion of vasopressin at low,
moderate or high doses (0.01 to 0.04 units/kg/hour) or dopamine
at low, moderate or high doses (5 to 20 mcg/kg/minute), titrated
to target an optimal mean blood pressure value. Outcomes that
7Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
will be evaluated are achievement of optimal mean blood pressure
(primary), ’all-cause mortality’, heart rate, serum lactate, sodium
and glucose levels, urine output, ischemic changes, feeding in-
tolerance, necrotizing enterocolitis (NEC), intestinal perforation,
severity of lung disease, symptomatic patent ductus arteriosus, se-
vere retinopathy of prematurity (ROP), chronic lung disease, in-
traventricular hemorrhage, periventricular leukomalacia, and neu-
rodevelopmental outcomes. The study started enrolling in March
2011 is expected to complete recruitment in 2013. This study was
excluded as the objective of this study was not to treat neonates
with refractory hypotension.
Risk of bias in included studies
We did not identify any eligible studies for inclusion.
Effects of interventions
We did not identify any eligible studies for inclusion.
D I S C U S S I O N
We did not identify any completed or ongoing studies that met
our inclusion criteria that randomized neonates with refractory
shock to vasopressin or its analogues. We identified and excluded
three randomized controlled studies in children but not neonates
(Yildizdas 2008; Baldasso 2009; Choong 2009) and one ongoing
randomized controlled study in neonates where the objective was
not to treat neonates with refractory hypotension (Rios 2011).
The randomized controlled trial (Yildizdas 2008) that included
children with an age range of one to 156 months suggests that
terlipressin can be safely used to increase the mean blood pressure
in children with catecholamine-resistant septic shock. Limitations
of this study include small sample size and risk of performance
bias as the investigators were not blinded to the intervention. Even
though terlipressin increased the mean blood pressure, improved
oxygenation, and decreased the length of pediatric intensive care
unit stay, it had no effects on mortality.
Challenges in summarizing data on vasopressin or terlipressin
therapy in neonates include variations in the dose and duration
of therapy and the heterogeneous study population in terms of
gestational age and underlying disease. Absence of randomized
controlled trials complicates unbiased assessment of clinical out-
comes including adverse effects. The evidence for the use of va-
sopressin and terlipressin in neonates is limited to case reports
(Matok 2004; Filippi 2008; Stathopoulos 2011) and case se-
ries (Matok 2005; Meyer 2006a; Meyer 2006b; Lechner 2007;
Leone 2008; Mastropietro 2008; Bidegain 2010; Ikegami 2010;
Rodriguez-Nunez 2010;Filippi 2011; Alten 2012). Vasopressin
and terlipressin were predominantly used to rescue neonates with
catecholamine-resistant and catecholamine- and corticosteroid-re-
sistant hypotension caused by sepsis (Matok 2004; Matok 2005;
Meyer 2006b; Bidegain 2010; Rodriguez-Nunez 2010; Filippi
2011), NEC (Bidegain 2010), post cardiac surgery (Lechner
2007; Mastropietro 2008; Alten 2012), systemic inflammatory re-
sponse syndrome (Filippi 2008), refractory pulmonary hyperten-
sion (Filippi 2011; Stathopoulos 2011), and acute kidney injury
(Meyer 2006a). The observations from the above studies suggest
that vasopressin and its analogue, terlipressin, can effectively in-
crease mean blood pressure both in extremely preterm and term
neonates with catecholamine-resistant shock.
Vasopressin or terlipressin-mediated increase in mean blood pres-
sure has not shown to be accompanied by improved survival or in-
creased end-organ perfusion. It is possible that vasopressin or ter-
lipressin were administered to rescue severely moribund neonates
late in the disease process. A trend towards increased mortality was
observed in children on low-dose vasopressin despite excluding
children who were terminally ill or who lacked commitment to life
support (Choong 2009). Vasopressin did not consistently improve
markers of end-organ perfusion, such as serum lactate, creatinine
or urine output and the effects were variable (Matok 2004; Matok
2005; Meyer 2006a; Lechner 2007; Filippi 2008; Mastropietro
2008; Bidegain 2010; Filippi 2011; Alten 2012). The ability of
terlipressin and vasopressin to decrease the inotrope score (Lechner
2007; Mastropietro 2008) and the need for catecholamines
(Matok 2005; Lechner 2007; Filippi 2008; Mastropietro 2008;
Bidegain 2010; Rodriguez-Nunez 2010; Filippi 2011) have been
reported. If this is found to be true in well-designed studies, vaso-
pressin or terlipressin can decrease the side-effects associated with
high-dose catecholamine therapy, such as arrhythmias, increased
myocardial oxygen consumption, and severe vasoconstriction.
Adverse effects of vasopressin and terlipressin have been re-
ported in some neonatal studies and include hyponatremia (Filippi
2011; Stathopoulos 2011; Alten 2012), cutaneous/limb ischemia
(Rodriguez-Nunez 2010), and liver necrosis (Meyer 2006a). Va-
sopressin or terlipressin use in neonates has not been associated
with NEC (Matok 2004; Meyer 2006a; Alten 2012). The safety
of vasopressin and its analogues needs to be assessed in prospective
randomized controlled studies in neonates. Given the limited ex-
perience with the use of vasopressin and its analogues in neonates,
it is not surprising that we could not find studies evaluating the
effects of vasopressin or terlipressin on the neurodevelopmental
outcomes, chronic lung disease, grade III or IV intraventricular
hemorrhage, periventricular leukomalacia, and ROP. Further re-
search is needed to clarify the role of vasopressin and its analogues
in neonatal refractory hypotension.
A U T H O R S ’ C O N C L U S I O N S
8Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Implications for practice
There is insufficient evidence to recommend or refute the use
of vasopressin or its analogue, terlipressin, in the safe and effec-
tive treatment of refractory hypotension in neonates. Importantly,
there is no information about the long-term neurodevelopmental
or pulmonary outcomes of neonates treated with vasopressin or
terlipressin.
Implications for research
Well-designed , adequately powered, randomized controlled stud-
ies are necessary to clarify the role of vasopressin and its analogues
in neonatal refractory hypotension. Specifically, studies should ad-
dress the efficacy, safety, indications for their use, timing of ther-
apy, optimal dosing, impact of treatment on major morbidities in
preterm infants such as necrotizing enterocolitis, intraventricular
hemorrhage, periventricular leukomalacia, retinopathy of prema-
turity, and especially long-term neurodevelopmental, pulmonary
outcomes and survival.
R E F E R E N C E S
References to studies excluded from this review
Baldasso 2009 {published data only}
Baldasso E, Garcia PC, Piva JP, Branco RG, Tasker RC. Pilot
safety study of low-dose vasopressin in non-septic critically
ill children. Intensive Care Medicine 2009;35(2):355–9.
Choong 2009 {published data only}
Choong K, Bohn D, Fraser DD, Gaboury I, Hutchison JS,
Joffe AR, et al.Vasopressin in pediatric vasodilatory shock: a
multicenter randomized controlled trial. American Journal
of Respiratory and Critical Care Medicine 2009;180(7):
632–9.
Rios 2011 {unpublished data only}
Rios DR, Gest AL. Study of dopamine versus vasopressin
for treatment of low blood pressure in low birth weight
infants. ClinicalTrials.gov 2011:NCT01318278.
Yildizdas 2008 {published data only}
Yildizdas D, Yapicioglu H, Celik U, Sertdemir Y, Alhan E.
Terlipressin as a rescue therapy for catecholamine-resistant
septic shock in children. Intensive Care Medicine 2008;34
(3):511–7.
Additional references
Al-Aweel 2001
Al-Aweel I, Pursley DM, Rubin LP, Shah B, Weisberger S,
Richardson DK. Variations in prevalence of hypotension,
hypertension, and vasopressor use in NICUs. Journal of
Perinatology 2001;21(5):272–8.
Alten 2012
Alten JA, Borasino S, Toms R, Law MA, Moellinger A,
Dabal RJ. Early initiation of arginine vasopressin infusion
in neonates after complex cardiac surgery. Pediatric Critical
Care Medicine 2012;13(3):300–4.
Argenziano 1998
Argenziano M, Chen JM, Choudhri AF, Cullinane S,
Garfein E, Weinberg AD, et al.Management of vasodilatory
shock after cardiac surgery: identification of predisposing
factors and use of a novel pressor agent. Journal of Thoracic
and Cardiovascular Surgery 1998;116(6):973–80.
Baker 2008
Baker CF, Barks JD, Engmann C, Vazquez DM, Neal CR
Jr, Schumacher RE, et al.Hydrocortisone administration
for the treatment of refractory hypotension in critically ill
newborns. Journal of Perinatology 2008;28(6):412–9.
Bell 1978
Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall
R, Barton L, et al.Neonatal necrotizing enterocolitis.
Therapeutic decisions based upon clinical staging. Annals of
Surgery 1978;187(1):1–7.
Bidegain 2010
Bidegain M, Greenberg R, Simmons C, Dang C, Cotten
CM, Smith PB. Vasopressin for refractory hypotension in
extremely low birth weight infants. Journal of Pediatrics
2010;157(3):502–4.
Dempsey 2006
Dempsey EM, Barrington KJ. Diagnostic criteria and
therapeutic interventions for the hypotensive very low birth
weight infant. Journal of Perinatology 2006;26(11):677–81.
Fanaroff 2006
Fanaroff AA, Fanaroff JM. Short- and long-term
consequences of hypotension in ELBW infants. Seminars in
Perinatology 2006;30(3):151–5.
Filippi 2008
Filippi L, Poggi C, Serafini L, Fiorini P. Terlipressin as rescue
treatment of refractory shock in a neonate. Acta Pediatrica
2008;97(4):500–2.
Filippi 2011
Filippi L, Gozzini E, Daniotti M, Pagliai F, Catarzi S,
Fiorini P. Rescue treatment with terlipressin in different
scenarios of refractory hypotension in newborns and infants.
Pediatric Critical Care Medicine 2011;12(6):e237–41.
Goldstein 1995
Goldstein RF, Thompson RJ, Jr, Oehler JM, Brazy JE.
Influence of acidosis, hypoxemia, and hypotension on
neurodevelopmental outcome in very low birth weight
infants. Pediatrics 1995;95(2):238–43.
Hegyi 1994
Hegyi T, Carbone MT, Anwar M, Ostfeld B, Hiatt M,
Koons A, et al.Blood pressure ranges in premature infants.
9Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
I. The first hours of life. Journal of Pediatrics 1994;124(4):
627–33.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1 [updated
March 2011]. The Cochrane Collaboration. Available from
www.cochrane-handbook.org.
Holmes 2001
Holmes CL, Patel BM, Russell JA, Walley KR. Physiology
of vasopressin relevant to management of septic shock.
Chest 2001;120(3):989–1002.
ICROP 1984
The Committee for the Classification of Retinopathy of
Prematurity. An international classification of retinopathy
of prematurity. The Committee for the Classification of
Retinopathy of Prematurity. Archives Ophthalmology 1984;
102(8):1130–4.
Ikegami 2010
Ikegami H, Funato M, Tamai H, Wada H, Nabetani
M, Nishihara M. Low-dose vasopressin infusion therapy
for refractory hypotension in ELBW infants. Pediatrics
International 2010;52(3):368–73.
Jobe 2001
Jobe AH, Bancalari E. Bronchopulmonary dysplasia.
American Journal of Respiratory and Critical Care Medicine
2001;163(7):1723–9.
Kusano 1997
Kusano E, Tian S, Umino T, Tetsuka T, Ando Y, Asano Y.
Arginine vasopressin inhibits interleukin-1 beta-stimulated
nitric oxide and cyclic guanosine monophosphate
production via the V1 receptor in cultured rat vascular
smooth muscle cells. Journal of Hypertension 1997;15(6):
627–32.
Lechner 2007
Lechner E, Hofer A, Mair R, Moosbauer W, Sames-
Dolzer E, Tulzer G. Arginine-vasopressin in neonates with
vasodilatory shock after cardiopulmonary bypass. European
Journal of Pediatrics 2007;166(12):1221–7.
Leone 2008
Leone M, Martin C. Role of terlipressin in the treatment
of infants and neonates with catecholamine-resistant septic
shock. Best Practice & Research. Clinical Anaesthesiology
2008;22(2):323–33.
Low 1993
Low JA, Froese AB, Galbraith RS, Smith JT, Sauerbrei EE,
Derrick EJ. The association between preterm newborn
hypotension and hypoxemia and outcome during the first
year. Acta Pediatrica 1993;82(5):433–7.
Mastropietro 2008
Mastropietro CW, Clark JA, Delius RE, Walters HL 3rd,
Sarnaik AP. Arginine vasopressin to manage hypoxemic
infants after stage I palliation of single ventricle lesions.
Pediatric Critical Care Medicine 2008;9(5):506–10.
Matok 2004
Matok I, Leibovitch L, Vardi A, Adam M, Rubinshtein M,
Barzilay Z, et al.Terlipressin as rescue therapy for intractable
hypotension during neonatal septic shock. Pediatric Critical
Care Medicine 2004;5(2):116–8.
Matok 2005
Matok I, Vard A, Efrati O, Rubinshtein M, Vishne T,
Leibovitch L, et al.Terlipressin as rescue therapy for
intractable hypotension due to septic shock in children.
Shock 2005;23(4):305–10.
Meyer 2006a
Meyer S, Gottschling S, Baghai A, Wurm D, Gortner L.
Arginine-vasopressin in catecholamine-refractory septic
versus non-septic shock in extremely low birth weight
infants with acute renal injury. Critical Care 2006;10(3):
R71.
Meyer 2006b
Meyer S, Loffler G, Polcher T, Gottschling S, Gortner
L. Vasopressin in catecholamine-resistant septic and
cardiogenic shock in very-low-birthweight infants. Acta
Paediatrica 2006;95(10):1309–12.
Miall-Allen 1987
Miall-Allen VM, de Vries LS, Whitelaw AG. Mean arterial
blood pressure and neonatal cerebral lesions. Archives of
Disease in Childhood 1987;62(10):1068–9.
Munro 2004
Munro MJ, Walker AM, Barfield CP. Hypotensive extremely
low birth weight infants have reduced cerebral blood flow.
Pediatrics 2004;114(6):1591–6.
Mutlu 2004
Mutlu GM, Factor P. Role of vasopressin in the management
of septic shock. Intensive Care Medicine 2004;30(7):
1276–91.
Nilsson 1990
Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E.
Pharmacokinetics of terlipressin after single i.v. doses to
healthy volunteers. Drugs Under Experimental and Clinical
Research 1990;16:307–14.
Nuntnarumit 1999
Nuntnarumit P, Yang W, Bada-Ellzey HS. Blood pressure
measurements in the newborn. Clinics in Perinatology 1999;
26(4):981–96.
Osborn 2001
Osborn DA, Evans N. Early volume expansion versus
inotrope for prevention of morbidity and mortality in very
preterm infants. Cochrane Database of Systematic Reviews
2001, Issue 2. [DOI: 10.1002/14651858.CD002056]
Osborn 2004
Osborn DA, Evans N. Early volume expansion for
prevention of morbidity and mortality in very preterm
infants. Cochrane Database of Systematic Reviews 2004, Issue
2. [DOI: 10.1002/14651858.CD002055]
Papile 1978
Papile LA, Burstein J, Burstein R, Koffler H. Incidence
and evolution of subependymal and intraventricular
hemorrhage: a study of infants with birth weights less than
1,500 gm. Journal of Pediatrics 1978;92(4):529–34.
10Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Paradisis 2004
Paradisis M, Osborn DA. Adrenaline for prevention
of morbidity and mortality in preterm infants with
cardiovascular compromise. Cochrane Database of
Systematic Reviews 2004, Issue 1. [DOI: 10.1002/
14651858.CD003958]
Patel 2002
Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial
effects of short-term vasopressin infusion during severe
septic shock. Anesthesiology 2002;96(3):576–82.
Pesaturo 2006
Pesaturo AB, Jennings HR, Voils SA. Terlipressin:
vasopressin analog and novel drug for septic shock. Annals
of Pharmacotherapy 2006;40(12):2170–7.
Pladys 1999
Pladys P, Wodey E, Beuchee A, Branger B, Betremieux P.
Left ventricular output and mean arterial blood pressure in
preterm infants during the 1st day of life. European Journal
of Pediatrics 1999;158(10):817–24.
RevMan 2011
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.1. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2011.
Rodriguez-Nunez 2006
Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J,
Hernandez A, Rey C. Rescue treatment with terlipressin
in children with refractory septic shock: a clinical study.
Critical Care 2006;10(1):R20.
Rodriguez-Nunez 2010
Rodriguez-Nunez A, Oulego-Erroz I, Gil-Anton J, Perez-
Caballero C, Lopez-Herce J, Gaboli M, et al.Continous
terlipressin infusion as rescue treatment in a case series
of children with refractory septic shock. The Annals of
Pharmacotherapy 2010;44(10):1545–53.
Sarkar 2007
Sarkar S, Dechert R, Schumacher RE, Donn SM. Is
refractory hypotension in preterm infants a manifestation of
early ductal shunting?. Journal of Perinatology 2007;27(6):
353–8.
Seri 2001
Seri I, Evans J. Controversies in the diagnosis and
management of hypotension in the newborn infant. Current
Opinion in Pediatrics 2001;13(2):116–23.
Stathopoulos 2011
Stathopoulos L, Nicaise C, Michel F, Thomachot L, Merrot
T, Lagier P, et al.Terlipressin as rescue therapy for refractory
pulmonary hypertension in a neonate with a congenital
diaphragmatic hernia. Journal of Pediatric Surgery 2011;46
(2):E19–21.
Subhedar 2003
Subhedar NV, Shaw NJ. Dopamine versus dobutamine
for hypotensive preterm infants. Cochrane Database
of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/
14651858.CD001242]
Subhedar 2007
Subhedar NV, Duffy K, Ibrahim H. Corticosteroids for
treating hypotension in preterm infants. Cochrane Database
of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/
14651858.CD003662]
Tsuji 2000
Tsuji M, Saul JP, Du Plessis A, Eichenwald E, Sobh
J, Crocker R, et al.Cerebral intravascular oxygenation
correlates with mean arterial pressure in critically ill
premature infants. Pediatrics 2000;106(4):625–32.
Volpe 2008
Volpe JJ. Hypoxic-ischemic encephalopathy:
neuropathology and pathogenesis. Neurology of the
Newborn. 5th Edition. Philadelphia: WB Saunders, 2008:
347–99.
Wakatsuki 1992
Wakatsuki T, Nakaya Y, Inoue I. Vasopressin modulates K
(+)-channel activities of cultured smooth muscle cells from
porcine coronary artery. American Journal of Physiology
1992;263(2 Pt 2):H491–6.
Wernovsky 1995
Wernovsky G, Wypij D, Jonas RA, Mayer JE Jr, Hanley FL,
Hickey PR, et al.Postoperative course and hemodynamic
profile after the arterial switch operation in neonates and
infants. A comparison of low-flow cardiopulmonary bypass
and circulatory arrest. Circulation 1995;92(8):2226–35.
Zeballos 2006
Zeballos G, Lopez-Herce J, Fernandez C, Brandstrup KB,
Rodriguez-Nunez A. Rescue therapy with terlipressin by
continuous infusion in a child with catecholamine-resistant
septic shock. Resuscitation 2006;68(1):151–3.∗ Indicates the major publication for the study
11Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baldasso 2009 Neonates were not included in the study
Choong 2009 Neonates were not included in the study
Rios 2011 The objective of this study was not to treat neonates with refractory hypotension
Yildizdas 2008 Neonates were not included in the study
12Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
This review has no analyses.
H I S T O R Y
Protocol first published: Issue 6, 2011
Review first published: Issue 3, 2013
Date Event Description
29 October 2008 New citation required and minor changes Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
BS and PM carried out the search, identified eligible articles and wrote the review
CF and DR assisted with the search, commented on the review and incorporated comments.
JR commented on the review and helped incorporate comments.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health,
Department of Health and Human Services, USA.
Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver
National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human
Services, USA, under Contract No. HHSN275201100016C.
13Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Hypotension [∗drug therapy]; Infant, Newborn; Lypressin [analogs & derivatives; therapeutic use]; Vasoconstrictor Agents [∗ therapeutic
use]; Vasopressins [∗therapeutic use]
MeSH check words
Humans
14Vasopressin and its analogues for the treatment of refractory hypotension in neonates (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.